Jeffrey Fudin, PharmD, DAIPM, FCCP, FASHP

The FDA approved cannabidiol (CBD) last year for the treatment of seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged 2 years and older. As pharmacists, we will likely be called upon as experts in CBD therapeutics. 
Millions worldwide dread the onset of debilitating migraines. There is a new drug class on the horizon that is thought to put a stop to the root of migraines. 
Despite a decline in the rate of opioid prescribing, the CDC reports that the number of opioid related deaths continues to rise. The pharmacology and pharmacokinetics of prescription and illicit fentanyl could help to shed light on why the opioid epidemic has taken the path that it has. 
Opioid allergies are often misdiagnosed. Improper allergy diagnosis may lead to delays in treatment and unnecessary drug avoidance. 
Although it is unclear what constitutes “unusual or disproportionate,” such phrases are particularly disturbing when we realize that the regulation of medical practice is a traditional state function, not a federal one.
A look at the different receptor bindings that affect analgesic effect.
The established therapeutic dosing for gabapentin in neuropathic pain is 1800-3600 mg/day in 3 divided doses in patients with normal renal function.
Here is how to distinguish between those who need prescriptions to manage pain and those seeking controlled substances for illicit reasons.
This testing has a positive clinical and therapeutic impact on dosage requirements and ethical considerations.
Prescribers and pharmacists in various clinical roles are often challenged when treating patients with comorbid chronic pain and end-stage renal disease (ESRD) or hemodialysis (HD). There is a dearth of clinical guidelines available for chronic pain management in this setting. Those selecting pharmacotherapy for patients must rely on clinical judgement, literature analysis and prudent decision making.
A recent New England Journal of Medicine publication addressed the rising costs of naloxone, but failed to address many of the hidden issue that are buried within routine pharmacy practice. Here we unveil some of the less obvious reasons and offer software solutions to help pharmacists safe lives.
Buprenorphine is one of the most commonly prescribed medications to treat opioid addiction. In 2014, about 60-65% of Americans using medication-assisted treatment received buprenorphine. On July 6, 2016, the Department of Health and Human Services (HHS) announced that it will raise the limit on the number of patients that can receive the addiction medicine buprenorphine to 275 patients per qualified provider. This article describes potential monetary conflicts in proving buprenorphine, how increased access will affect pharmacists and what they can do to help patients in need of medication supported abstinence and substance abuse counseling.
+ Load More